How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,762 results for

Cardiogenic Shock

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Defining cardiogenic shock and comparing treatment modalities: a systematic review

Defining cardiogenic shock and comparing treatment modalities: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2020 PROSPERO

162. Impella Recover LP 2.5 percutaneous cardiac support system (Abiomed Inc.) for emergent hemodynamic support in patients with cardiogenic shock

Impella Recover LP 2.5 percutaneous cardiac support system (Abiomed Inc.) for emergent hemodynamic support in patients with cardiogenic shock Impella Recover LP 2.5 percutaneous cardiac support system (Abiomed Inc.) for emergent hemodynamic support in patients with cardiogenic shock Impella Recover LP 2.5 percutaneous cardiac support system (Abiomed Inc.) for emergent hemodynamic support in patients with cardiogenic shock Record Status This is a bibliographic record of a published health (...) technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Impella Recover LP 2.5 percutaneous cardiac support system (Abiomed Inc.) for emergent hemodynamic support in patients with cardiogenic shock. Lansdale: HAYES, Inc.. Health Technology Brief Publication. 2013 Authors' conclusions Approximately 6% to 15% of patients with acute myocardial infarction (AMI) present with or develop cardiogenic shock (CS) mainly due to left ventricular (LV

2013 Health Technology Assessment (HTA) Database.

163. Levosimendan in cardiogenic shock secondary to acute myocardial infarction (AMI)

Levosimendan in cardiogenic shock secondary to acute myocardial infarction (AMI) BestBets: Levosimendan in cardiogenic shock secondary to acute myocardial infarction (AMI) Levosimendan in cardiogenic shock secondary to acute myocardial infarction (AMI) Report By: Jonathon Coates - Registrar Emergency Medicine & Intensive Care Medicine Search checked by Steve Mathieu - Consultant, Intensive Care Medicine & Anaesthetics Institution: Queen Alexandra Hospital, Portsmouth, UK Original institution (...) : Queen Alexandra Hospital, Portsmouth, UK Date Submitted: 15th September 2013 Date Completed: 26th February 2014 Last Modified: 26th February 2014 Status: Green (complete) Three Part Question In [adults suffering from a STEMI complicated by cardiogenic shock] does [treatment with levosimendan] [improve outcome]? Clinical Scenario A 56 year old is brought to the ED suffering from a STEMI. He is hypotensive and suffering from cardiogenic shock. He has been started on dobutamine but he has failed

2014 BestBETS

164. Evaluation of Intra-Aortic Balloon Support in cardiogenic shock.

Evaluation of Intra-Aortic Balloon Support in cardiogenic shock. BestBets: Evaluation of Intra-Aortic Balloon Support in cardiogenic shock. Evaluation of Intra-Aortic Balloon Support in cardiogenic shock. Report By: Dr. Joseph Humphrey and Dr Bryan Judge - Emergency Medicine Residents Search checked by Bernard A Foex - Consultant in Emergency Medicine and Critical Care Institution: Grand Rapids Medical Education Research Partners/Michigan State University, Michigan, USA Original institution (...) : Manchester Royal Infirmary, Oxford Road, Manchester, UK Date Submitted: 15th May 2013 Date Completed: 26th February 2014 Last Modified: 26th February 2014 Status: Green (complete) Three Part Question In [adult patients with cardiogenic shock following myocardial infarction ] [what is the usefulness] of [intra-aortic balloon support]? Clinical Scenario A 67-year-old man is brought to the emergency department. He is cold, clammy and confused. He is also hypotensive and an ECG shows that he has had an AMI

2014 BestBETS

165. Removal notice to “Erratum to: Intraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock: Design and rationale of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial” [Am Heart J. 169/1 (Abstract)

Removal notice to “Erratum to: Intraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock: Design and rationale of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial” [Am Heart J. 169/1 25646555 2015 03 30 2019 02 25 1097-6744 169 1 2015 Jan American heart journal Am. Heart J. Removal notice to “Erratum to: Intraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock: Design (...) and rationale of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial” [Am Heart J. 169/1 (2014) 185]. R1 10.1016/j.ahj.2014.12.007 eng Retraction of Publication United States Am Heart J 0370465 0002-8703 Am Heart J. 2015 Jan;169(1):185 25654141 2015 2 4 6 0 2015 2 4 6 0 2015 3 31 6 0 ppublish 25646555 S0002-8703(14)00744-3 10.1016/j.ahj.2014.12.007

2015 American Heart Journal Controlled trial quality: uncertain

166. Fibroblast growth factor 23 in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial. Full Text available with Trip Pro

Fibroblast growth factor 23 in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial. Cardiogenic shock (CS) is the leading cause of death in patients hospitalized with acute myocardial infarction (AMI). Biomarkers might help in risk stratification and understanding of pathophysiology. Preliminary data suggests that patients with CS face a profound increase in the osteocyte-derived hormone (...) fibroblast growth factor 23 (FGF-23), which acts as a negative regulator of serum phosphate levels. The present study aimed to assess the predictive role of FGF-23 for clinical outcome in a large cohort of CS patients with and without renal dysfunction.In the randomized Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial, 600 patients with CS complicating AMI were assigned to therapy with or without IABP. Our predefined biomarker substudy included 182 patients. Blood sampling

2015 Critical care (London, England) Controlled trial quality: uncertain

167. Intraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock: Design and rationale of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial. (Abstract)

Intraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock: Design and rationale of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial. 25819870 2015 05 18 2018 12 02 1097-6744 169 4 2015 Apr American heart journal Am. Heart J. Intraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock: Design and rationale of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial. e7 (...) Institut für Herzinfarktforschung Ludwigshafen, Ludwigshafen, Germany; Heart Center Ludwigshafen, Ludwigshafen, Germany Ludwigshafen, Ludwigshafen, Germany. IABP-SHOCK II Trial Investigators eng Letter Comment 2015 01 30 United States Am Heart J 0370465 0002-8703 AIM IM Am Heart J. 2012 Jun;163(6):938-45 22709745 Humans Intra-Aortic Balloon Pumping Myocardial Infarction complications Shock, Cardiogenic therapy 2015 3 31 6 0 2015 3 31 6 0 2015 5 20 6 0 ppublish 25819870 S0002-8703(15)00059-9 10.1016

2015 American Heart Journal Controlled trial quality: uncertain

168. REMOVED: “Erratum to: Intraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock: Design and rationale of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial”. (Abstract)

REMOVED: “Erratum to: Intraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock: Design and rationale of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial”. 25654141 2015 03 30 2018 10 23 1097-6744 169 1 2015 Jan American heart journal Am. Heart J. REMOVED: “Erratum to: Intraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock: Design and rationale of the Intraaortic Balloon Pump (...) in Cardiogenic Shock II (IABP-SHOCK II) trial”. 185 10.1016/j.ahj.2014.11.001 eng Published Erratum Retracted Publication United States Am Heart J 0370465 0002-8703 Am Heart J. 2012 Jun;163(6):938-45 22709745 Am Heart J. 2015 Jan;169(1):R1 25646555 2015 2 6 6 0 2015 2 6 6 0 2015 2 6 6 1 ppublish 25654141 S0002-8703(14)00660-7 10.1016/j.ahj.2014.11.001

2015 American Heart Journal Controlled trial quality: uncertain

169. One-Year Outcomes after different PCI Strategies in Cardiogenic Shock.

One-Year Outcomes after different PCI Strategies in Cardiogenic Shock. One-Year Outcomes after different PCI Strategies in Cardiogenic Shock. – Less Is More Search for: Simpler & Better Medicine Menu / Summary: For patients with acute myocardial infarction and cardiogenic shock due to multi-vessel coronary artery disease, an approach of culprit-lesion-only percutaneous coronary intervention (PCI) may be associated with lower rates of death or severe renal failure at 30-day follow-up compared

2018 Less Is More Blog

170. Cardiogenic shock with wide complex tachycardia and poor LV function in a young woman

Cardiogenic shock with wide complex tachycardia and poor LV function in a young woman Dr. Smith's ECG Blog: Cardiogenic shock with wide complex tachycardia and poor LV function in a young woman Saturday, October 14, 2017 A 30-something woman presented with CP and SOB. She was hypoxic and intubated. She had very poor LV systolic function on bedside echo. There were no B-lines and the RV was normal. The following ECG was recorded: Wide complex regular tachycardia at a rate of 140, no P-waves What (...) remained in cardiogenic shock due to severely decreased LV systolic function. The remainder of the management is beyond the scope of this blog. Later in the day, this ECG was recorded: Sinus with LBBB. So the LBBB is definitely baseline. This is the same morphology that she had while in tachycardia, proving that the rhythm was supraventricular. The patient recovered neurologically, but with a persistently very low ejection fraction (20%, due to new cardiomyopathy). She also had very frequent

2017 Dr Smith's ECG Blog

171. One-Year Outcomes after different PCI Strategies in Cardiogenic Shock.

One-Year Outcomes after different PCI Strategies in Cardiogenic Shock. One-Year Outcomes after different PCI Strategies in Cardiogenic Shock. – Less Is More Search for: Simpler & Better Medicine Menu / Summary: For patients with acute myocardial infarction and cardiogenic shock due to multi-vessel coronary artery disease, an approach of culprit-lesion-only percutaneous coronary intervention (PCI) may be associated with lower rates of death or severe renal failure at 30-day follow-up compared

2018 Less Is More Blog

172. Venoarterial Extracorporeal Membrane Oxygenation for Refractory Cardiogenic Shock in Elderly Patients: Trends in Application and Outcome From the Extracorporeal Life Support Organization (ELSO) Registry. Full Text available with Trip Pro

Venoarterial Extracorporeal Membrane Oxygenation for Refractory Cardiogenic Shock in Elderly Patients: Trends in Application and Outcome From the Extracorporeal Life Support Organization (ELSO) Registry. Venoarterial extracorporeal membrane oxygenation (VA-ECMO) for refractory cardiogenic shock (RCS) is increasingly used in adult patients, but age represents a controversial factor in this setting.Data from the Extracorporeal Life Support Organization registry was analyzed to assess in-hospital

2017 Annals of Thoracic Surgery

173. Effects of Low-Dose Recombinant Human Brain Natriuretic Peptide on Anterior Myocardial Infarction Complicated by Cardiogenic Shock. Full Text available with Trip Pro

Effects of Low-Dose Recombinant Human Brain Natriuretic Peptide on Anterior Myocardial Infarction Complicated by Cardiogenic Shock. The mortality due to cardiogenic shock complicating acute myocardial infarction (AMI) is high even in patients with early revascularization. Infusion of low dose recombinant human brain natriuretic peptide (rhBNP) at the time of AMI is well tolerated and could improve cardiac function.The objective of this study was to evaluate the hemodynamic effects of rhBNP (...) in AMI patients revascularized by emergency percutaneous coronary intervention (PCI) who developed cardiogenic shock.A total of 48 patients with acute ST segment elevation myocardial infarction (STEMI) complicated by cardiogenic shock and whose hemodynamic status was improved following emergency PCI were enrolled. Patients were randomly assigned to rhBNP (n=25) and control (n=23) groups. In addition to standard therapy, study group individuals received rhBNP by continuous infusion at 0.005 µg kg-1

2017 Brazilian journal of cardiovascular surgery Controlled trial quality: uncertain

174. SafeTy and Outcome of contemPorary Treatment Strategies for Cardiogenic SHOCK

SafeTy and Outcome of contemPorary Treatment Strategies for Cardiogenic SHOCK SafeTy and Outcome of contemPorary Treatment Strategies for Cardiogenic SHOCK - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . SafeTy and Outcome of contemPorary Treatment Strategies for Cardiogenic SHOCK (STOP-SHOCK) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03313687 Recruitment Status : Recruiting First Posted : October 18, 2017 Last

2017 Clinical Trials

175. Norepinephrine vs Norepinephrine and Dobutamine in Cardiogenic Shock

Norepinephrine vs Norepinephrine and Dobutamine in Cardiogenic Shock Norepinephrine vs Norepinephrine and Dobutamine in Cardiogenic Shock - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Norepinephrine vs (...) Norepinephrine and Dobutamine in Cardiogenic Shock (SHOCK-NORDOB) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03340779 Recruitment Status : Not yet recruiting First Posted : November 14, 2017 Last Update Posted : November 14

2017 Clinical Trials

176. Impact of Adrenoreceptor Expressions on Inflammatory Pattern in Refractory Cardiogenic Shock Under VA ECMO

Impact of Adrenoreceptor Expressions on Inflammatory Pattern in Refractory Cardiogenic Shock Under VA ECMO Impact of Adrenoreceptor Expressions on Inflammatory Pattern in Refractory Cardiogenic Shock Under VA ECMO - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100 (...) ). Please remove one or more studies before adding more. Impact of Adrenoreceptor Expressions on Inflammatory Pattern in Refractory Cardiogenic Shock Under VA ECMO (ADRECMO) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier

2017 Clinical Trials

177. Prolonged circulatory support with an Impella assist device in the management of cardiogenic shock associated with takotsubo syndrome, severe sepsis and acute respiratory distress syndrome Full Text available with Trip Pro

Prolonged circulatory support with an Impella assist device in the management of cardiogenic shock associated with takotsubo syndrome, severe sepsis and acute respiratory distress syndrome Severe sepsis has been known to trigger for takotsubo syndrome which is associated with profound physical or emotional stress. Severe sepsis is also associated with sepsis-induced cardiomyopathy, a reversible myocardial depression. We report a case in which a patient with takotsubo syndrome, cardiogenic shock (...) , severe sepsis, and adult respiratory distress syndrome was managed with an Impella Cardiac Power circulatory support device for 108 h (4.5 days) because of sustained hemodynamic compromise. To the best of our knowledge, this represents the longest reported use of the Impella Cardiac Power device for the management of cardiogenic shock in a patient with takotsubo syndrome and severe sepsis. This report also highlights the importance of considering a ventricular assist device in the management

2017 SAGE Open Medical Case Reports

178. Cardiogenic Shock Secondary to Takotsubo Cardiomyopathy in a Patient with Preexisting Hypertrophic Obstructive Cardiomyopathy Full Text available with Trip Pro

Cardiogenic Shock Secondary to Takotsubo Cardiomyopathy in a Patient with Preexisting Hypertrophic Obstructive Cardiomyopathy 30062317 2019 02 26 2468-6441 2 3 2018 Jun CASE (Philadelphia, Pa.) CASE (Phila) Cardiogenic Shock Secondary to Takotsubo Cardiomyopathy in a Patient with Preexisting Hypertrophic Obstructive Cardiomyopathy. 78-81 10.1016/j.case.2017.09.008 Nalluri Nikhil N Department of Cardiology, Staten Island University Hospital, Staten Island, New York. Asti Deepak D Department

2017 CASE : Cardiovascular Imaging Case Reports

179. Incidence and risk factors of groin lymphocele formation after venoarterial extracorporeal membrane oxygenation in cardiogenic shock patients. Full Text available with Trip Pro

Incidence and risk factors of groin lymphocele formation after venoarterial extracorporeal membrane oxygenation in cardiogenic shock patients. Venous-arterial extracorporeal membrane oxygenation (VA-ECMO) is a well-established therapy for refractory cardiopulmonary failure. Femoral cannulation offers a quick and effective means of providing circulatory support but is not without complication. Inflammation or lymphatic disruption at the site of cannulation can cause the formation of lymphoceles (...) , leading to the patient's discomfort and possibly necessitating intervention. The purpose of this study was to evaluate the incidence of in-hospital lymphocele formation in VA-ECMO patients and to identify predictors for their development.We conducted a single-center retrospective review of 192 patients who underwent femoral VA-ECMO insertion and subsequent decannulation from March 2007 to August 2016 for cardiogenic shock. Baseline demographics, risk factors, and cannulation strategies were examined

2017 Journal of Vascular Surgery

180. Frequency and Prognostic Significance of Abnormal Liver Function Tests in Patients With Cardiogenic Shock. Full Text available with Trip Pro

Frequency and Prognostic Significance of Abnormal Liver Function Tests in Patients With Cardiogenic Shock. Cardiogenic shock (CS) is a cardiac emergency often leading to multiple organ failure and death. Assessing organ dysfunction and appropriate risk stratification are central for the optimal management of these patients. The purpose of this study was to assess the prevalence of abnormal liver function tests (LFTs), as well as early changes of LFTs and their impact on outcome in CS. We

2017 American Journal of Cardiology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>